536 related articles for article (PubMed ID: 21763968)
21. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for renal cell cancer.
Yang JC; Childs R
J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
[TBL] [Abstract][Full Text] [Related]
24. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Négrier S; Philip T
Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
[TBL] [Abstract][Full Text] [Related]
25. [Interferon-alpha therapy in hypernephroma].
Sagaster KP
Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF
Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
[TBL] [Abstract][Full Text] [Related]
27. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of renal cell carcinoma with mediastinal lymph node metastasis by interleukin-2: a case report.
Tokunaga M; Masuda A; Mukai M; Nakamura H; Iwaki K; Terachi T
Tokai J Exp Clin Med; 2005 Jul; 30(2):111-5. PubMed ID: 16146201
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for metastatic renal cell carcinoma.
Wirth MP
Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
[TBL] [Abstract][Full Text] [Related]
30. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
Ernstoff MS; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Farnham CJ; Mackay K; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):733s-740s. PubMed ID: 17255302
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
32. Characterization of primary renal carcinoma cultures.
Sievers E; Dreimuller P; Haferkamp A; Schmidt-Wolf IG; Buchler MW; Schmidt J; Marten A
Urol Int; 2007; 79(3):235-43. PubMed ID: 17940356
[TBL] [Abstract][Full Text] [Related]
33. Cytokine therapy for metastatic renal cell carcinoma.
Bukowski RM
Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
Schmitz-Dräger BJ; Jankevicius F; Otto T
Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
[TBL] [Abstract][Full Text] [Related]
35. [Immunology in clinical practice. XVII. Immunotherapy of metastatic renal cell carcinoma. Work Group Immunotherapy, Dutch Oncology].
van Herpen CM; de Mulder PH
Ned Tijdschr Geneeskd; 1998 Nov; 142(48):2613-8. PubMed ID: 10028361
[TBL] [Abstract][Full Text] [Related]
36. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.
Atkins MB; Regan M; McDermott D
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028
[TBL] [Abstract][Full Text] [Related]
37. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for renal carcinoma: theoretical basis and current standard of care.
Vasey PA
Br J Clin Pharmacol; 2000 Dec; 50(6):521-9. PubMed ID: 11136291
[No Abstract] [Full Text] [Related]
39. [Cytokine therapy of metastatic renal cell carcinoma].
Otto T; Goepel M; Luboldt HJ; Rübben H
Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
[TBL] [Abstract][Full Text] [Related]
40. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
